We are improving the lives of people suffering from mental illness and substance use disorders

 

What we do

US Pharma

US Pharma

HQ & Pipeline

HQ & Pipeline

Digital Therapeutics

Digital Therapeutics

 Discover our story 

Key News

FEBRUARY 3, 2023
NDA submitted with the FDA for OX124 a highdose medication for opioid overdose

JANUARY 26, 2023
Orexo Interim Report Q4 2022, incl. Full Year Report

JANUARY 25, 2023
New blog post - "Charlie’s overdose: why we need to tell young people about fake pills"

Listed on Nasdaq Stockholm´s mainlist

Orexo is listed on Nasdaq Stockholm´s main list and can also be traded in the US at the OTCQX Market.

MODIA® - our digital therapy for opioid use disorder

  • to be used along with pharmaceuticals
  • 180 days treatment
  • grounded in cognitive behavioral therapy techniques
  • available 24/7
  • ongoing clinical trial incl. more than 430 patients

Orexo Social

3 February 2023

Life Science Sweden om att vi lämnat in en FDA-ansökan om att få OX124 - vårt överdosläkemedel - godkänt i USA.… https://t.co/pAjhD063kD

3 February 2023

#Orexo has filed a New Drug Application to the FDA for OX124, our life-saving medication that reverses the effects… https://t.co/WbspScyY7k

31 January 2023

Klas Palin, hälsovårdsanalytiker på Erik Penser Bank, i en lång intervju med VD Nikolaj Sørensen. På agendan: Opera… https://t.co/8nhwCYB7hL

Financial Snapshot

Group net revenues

624.3  MSEK

LTM1

Group EBITDA

-115.2 MSEK

LTM1

US Pharma segment EBIT

308.4 MSEK

LTM1

Cash position

359.1 MSEK

Q4 2022

1 Last Twelve Months, Q122-Q422, for more information about financial development Link